These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15201230)

  • 41. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
    Pulido F; Arribas JR; Miró JM; Costa MA; González J; Rubio R; Peña JM; Torralba M; Lonca M; Lorenzo A; Cepeda C; Vázquez JJ; Gatell JM;
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):343-50. PubMed ID: 15097150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma.
    Stebbing J; Gazzard B; Mandalia S; Teague A; Waterston A; Marvin V; Nelson M; Bower M
    J Clin Oncol; 2004 Jun; 22(11):2177-83. PubMed ID: 15169806
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients.
    Campo RE; Cohen C; Grimm K; Shangguan T; Maa J; Seekins D
    Int J STD AIDS; 2010 Mar; 21(3):166-71. PubMed ID: 20215619
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
    Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
    Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
    Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
    HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
    Moyle G
    Drugs; 2001; 61(1):19-26. PubMed ID: 11217868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
    Manosuthi W; Sungkanuparph S; Vibhagool A; Rattanasiri S; Thakkinstian A
    HIV Med; 2004 Mar; 5(2):105-9. PubMed ID: 15012650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.
    Annan NT; Nelson M; Mandalia S; Bower M; Gazzard BG; Stebbing J
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):140-6. PubMed ID: 19352201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    Crane HM; Van Rompaey SE; Kitahata MM
    AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease.
    Esposito A; Floridia M; d'Ettorre G; Pastori D; Fantauzzi A; Massetti P; Ceccarelli G; Ajassa C; Vullo V; Mezzaroma I
    BMC Infect Dis; 2011 Dec; 11():341. PubMed ID: 22166160
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
    Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
    Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
    Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
    AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides.
    Barreiro P; Soriano V; Casas E; González-Lahoz J
    AIDS; 2002 Jan; 16(2):245-9. PubMed ID: 11807309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
    Torti C; d'Arminio-Monforte A; Pozniak AL; Lapadula G; Cologni G; Antinori A; De Luca A; Mussini C; Castagna A; Cicconi P; Minoli L; Costantini A; Carosi G; Liang H; Cesana BM;
    BMC Infect Dis; 2011 Jan; 11():23. PubMed ID: 21266068
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.
    Chou R; Fu R; Huffman LH; Korthuis PT
    Lancet; 2006 Oct; 368(9546):1503-15. PubMed ID: 17071284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.